Psychological distress is frequently reported in transplant survivors. We prospectively assessed anxiety and depression before transplant, in the isolation period and during a follow-up period of 1 year. The Hospital Anxiety and Depression Scale (HADS) was administered to 131 cancer patients treated with high-dose chemotherapy followed by allogeneic (SCT) or autologous (ASCT) stem cell transplantation, and a concurrent group of 123 lymphoma patients receiving standard chemotherapy (CT) who served as a reference group. Relatively low levels of anxiety and depression were found. The level of anxiety slightly declined from baseline during follow-up (mean scores SCT: from 5.3 to 3.6, CT: from 6.0 to 4.2) or remained fairly stable (ASCT: from 5.4 to 4.8). The level of depression peaked when the transplant patients were in protective isolation or shortly thereafter (SCT: 6.1, ASCT: 6.4), but stabilized at baseline levels after 4 months. The highest level of depression in the CT group was reported 4 months after start of chemotherapy (3.4). Elevated levels of anxiety and depression at baseline predicted more anxiety and depression at the later assessments (P values Ͻ0.0001). The ASCT group had higher levels of anxiety after 1 year (mean 4.8) than those found in the other two groups (SCT: 3.6, CT: 4.2), although they were not statistically significant. This study revealed lower than expected levels of anxiety and depression after intensive chemotherapy followed by SCT or ASCT. There was a decline in psychological distress during the 1-year follow-up period. Keywords: anxiety; depression; HADS; high-dose chemotherapy; prospective study Allogeneic (SCT) and autologous (ASCT) stem cell transplantation subsequent to high-dose chemotherapy (HDC) produces significant physical morbidity.
data on the prevalence and severity of psychological morbidity are important. In order to identify patients with symptoms of anxiety and depression in the early stages of disease and treatment, who might be at risk of psychological maladjustment after such intensive treatment, it is important to raise the awareness of signs of psychological distress in clinical oncology. A routine-based incorporation of assessment of anxiety and depression might be helpful.
Previous studies which have used questionnaires such as the Profile of Moods State (POMS) or the Brief Symptom Inventory (BSI) for the evaluation of anxiety and depression, have shown that psychological distress is frequently reported by SCT and ASCT patients. The percentages of patients with these problems vary from 14% to 41%, depending on the study design, types of measures, and time of assessment relative to diagnoses and treatment. [3] [4] [5] [6] [7] [8] [9] When data from transplant patients have been compared with data from the general population, higher psychiatric case rates have been found in the patients, such as 22% vs 9% on the General Health Questionnaire (GHQ). 3 Twice as much psychiatric morbidity was found by the POMS 7 with 14% of the patients scoring at least 1.5 s.d. above the norm; a cut-off for psychiatric disorder. Others have reported significantly higher levels of anxiety and depression when using the POMS and BSI. 4, 10 The Hospital and Anxiety Depression scale (HADS) 11 has been developed for evaluation of anxiety and depression in physically ill patients and has been frequently used in various cancer populations, both with in patients and outpatients. [12] [13] [14] [15] [16] [17] [18] [19] We identified six studies which have employed the HADS in SCT and ASCT patients; two crosssectional, 20, 21 one retrospective 22 and three prospective. [23] [24] [25] No significant differences in anxiety or depression were found between 53 SCT and 38 ASCT patients at a mean of 40 months post transplant, but they were significantly less depressed when compared to 73 patients receiving maintenance chemotherapy. 20 Twelve percent of the transplant patients were defined as definite anxiety cases (scale score Ͼ10) and 11% as probable cases (scale score 8 to 10). The percentages for depression were 6% and 2% respectively, relative to 6% and 8% in the chemotherapy group. 20 Clinical signs of anxiety were reported in 20% and of depression in 10% of 24 ASCT patients relative to 10% and 0% in 26 SCT patients retrospectively assessed by the HADS scale. 21 A 40% prevalence of depression related to impaired physical function was reported in a retrospective report of 16 SCT and 17 ASCT patients who completed the HADS scale shortly after discharge. 22 In the prospective reports, about 30% of patients were defined as clinical cases of anxiety 25 or anxiety and depression combined at baseline. 24 Baseline scores were strong predictors for psychosocial morbidity 6 to 9 months following transplant, 23 while no such predictive power was demonstrated by Jenkins et al. 24 The limiting factor in these studies was the small numbers of patients assessed at baseline and the last assessment, respectively; 36 and 16, 23 30 and 12, 24 12 and 8. 25 Furthermore, mean scores from different numbers of patients at baseline and the subsequent assessments were reported.
A prospective design as employed in this study is probably the best method for examining whether post-transplant psychological distress is directly attributable to the intensive treatment or related to other factors. Tross and Holland 26 describe psychological problems related to the initial diagnosis and treatment as different from psychological sequelae in cancer survivors. Illness-related concerns, an anticipatory response to death and a residual response to diagnosis and treatment are elements of this reaction. Based on our clinical experience and findings from the literature, we expect the intensity of the treatment with HDC followed by transplantation to act as a potential psychological stressor on patients. We therefore expected these patients to report elevated levels of anxiety and depression, in particular prior to and during the isolation period, but also to experience psychological distress well beyond this period. Furthermore, we anticipated a different course of adjustment in the reference group, peaking at the time around diagnosis and start of treatment.
The aims of this report are two-fold: (1) To describe the course of anxiety and depression in transplant patients and in a group of lymphoma patients treated with combination chemotherapy (CT group) at baseline, during treatment and follow-up which is defined as 1 year after transplant (SCT and ASCT groups) or start of chemotherapy (CT group). (2) To examine the relationship between background variables and psychological distress.
Materials and methods

Patients
Over a 3-year period starting in April 1993, all consecutive leukemia patients who were considered for allogeneic stem cell transplantation (SCT group) at the National Hospital and all patients with malignant lymphoma who were evaluated for autologous stem cell transplantation (ASCT group) at the Norwegian Radium Hospital (NRH) were contacted. Simultaneously, all lymphoma patients who were admitted to the NRH for diagnostic verification and start of primary chemotherapy were recruited to serve as a reference group (CT group). Seventy-six SCT, 85 ASCT and 161 CT patients were approached. Eight SCT patients and 11 ASCT patients did not proceed to transplant, two SCT patients were treated abroad, four SCT and five ASCT patients declined participation, while 38 patients in the CT group were ineligible after revision of diagnoses and change of therapy. 27 The baseline questionnaire was completed by 62 SCT patients, 69 ASCT patients and 123 CT patients. One SCT patient and five CT patients, however, were excluded from analyses because they only filled in the first questionnaire due to unknown reasons (four) and critical illness and death (two) (Figure 1) . A questionnaire packet including the HADS was then sent by mail eight times to the SCT and ASCT patients and six times to the CT patients during follow-up. During the year of follow-up, 15 SCT patients, eight ASCT patients and nine CT patients died. Eight SCT patients, 14 ASCT patients and 19 CT patients withdrew from the study, while five CT patients relapsed and were accepted on to the ASCT program ( Figure 1 ). We wanted to have one additional pre-transplant assessment and one assessment during the isolation period in the SCT and ASCT groups. Therefore, the number of assessments in the transplant groups and the CT group differs.
Additionally, four assessments were regarded as critical time points for the SCT and ASCT patients in particular, based on clinical experience and findings from the literature. To examine the temporal trajectory, data from the same number of patients are reported from these four assessments; baseline, 1 and 6 months and 1 year post transplant.
The majority of SCT patients (51%) suffered from chronic myelogenous leukemia (CML), 19 (31%) had acute myeloid leukemia and 11 patients (18%) had acute lymphoblastic leukemia ( Table 1 ). The distribution of lymphoma diagnoses among the ASCT and the CT groups was significantly different (P Ͻ 0.0001) as expected, due to the different indications related to each treatment. No significant differences were found with respect to sociodemographic variables.
SCT and ASCT groups
Significantly more SCT patients were in first complete remission or in chronic phase of CML at the time of transplant, compared with the ASCT group (72% vs 10%, P Ͻ 0.0001) ( Table 2) . As a group, the ASCT patients had undergone more chemotherapy of higher intensity over a longer period of time than the SCT patients. All ASCT patients had received combination chemotherapy according to standard treatment protocols prior to transplant, compared with 30 SCT patients (49%), those suffering from AML or ALL. Thirty SCT patients with CML had received hydroxyurea; as monotherapy (17) , or in combination with interferon ␣2b (11) , or busulphan (two), while one patient had received no treatment. One SCT patient (2%) had received additional radiotherapy to the central nervous system as part of primary treatment, compared with 19 (28%) of the ASCT patients (P Ͻ 0.0001). The SCT patients spent significantly more days (34 vs 20, P Ͻ 0.0001) in protective isolation than the ASCT patients.
Twenty-six SCT patients (43%) suffered from acute graft-versus-host disease (GVHD) during hospitalization; grade 1 in 10, grade 2 in 10, grade 3 in three and grade 4 in three. Eleven of 41 SCT patients (27%) had chronic GVHD at the 1-year medical examination, two extensive b Patients who failed to fill in a single questionnaire, but who wanted to remain in the study.
c Because inclusion was less than 1 month prior to transplant, questionnaires were not administered to five SCT and nine ASCT patients. Patients who failed to respond after one reminder or who declined further participation on the provided statement coupons: withdrawn from the sample.
e Accepted on to the ASCT programme due to relapse or disease progression.
disease. Sixty-nine percent of the SCT and ASCT patients were working or studying at the 1-year assessment.
CT group
All CT patients received conventional chemotherapy according to the underlying disease. The CHOP regimen (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) was used most frequently (34%). Fifty-four patients (46%) received additional radiotherapy, with mantle and mediastinal fields being most often administered, given to 16 (30%) and 12 patients (22%), respectively. One year after the start of chemotherapy, 73% of the 85 patients who remained in the study were in complete remission, and 65% of the 78 patients who had been working or studying at the time of diagnoses had resumed these activities.
The Hospital Anxiety and Depression scale (HADS)
In the development of the Hospital Anxiety and Depression Scale (HADS) 11 effort was made not to include items which might also be symptoms of physical illness, such as insomnia or loss of appetite. HADS has been recommended for use in cancer patients. 28 HADS contains 14 questions, each with four categorical answers going from zero to three. There are two scales, one for anxiety (seven questions) and one for depression (seven questions). The total score of each scale, derived by simple addition, indicates the extent of anxiety and depression, with higher scores meaning more distress. It has been successfully validated against other psychiatric scales 12, 17, 29, 30 and recommended for use as a screening instrument. 14, 19, 24, 29 Two cut-off points for the definition of cases on each scale are suggested by the authors:
11 a mean scale score of 8 to 10 is defined as a possible case, and 11 or higher is defined as a definite case. The lower threshold was used in this study in order to detect possible cases who might benefit from intervention programs.
Karnofsky performance status scale
The Karnofsky performance status scale (KPS) 31 is an observer rated scale which is frequently used to evaluate the physical function of a patient. It contains 11 categories going from 0% meaning death to 100% indicating normal performance. The KPS of the transplant patients was filled in by the clinicians while the patients were in the isolation unit, and when they came for the 1 year medical examination.
Data analyses
Statistical procedures included chi-square tests (nominal categorical variables), Kruskal-Wallis analyses of variance, Wilcoxon's and t-tests (two-sided) for independent samples, Pearson's correlations and multiple and logistic regression analyses. A 0.01 level of statistical significance was used with all tests to reduce the impact of multiple testing. If a questionnaire was missing but the patients stated upon request that they wanted to continue the study, they were not excluded. Those who failed to fill in two consecutive questionnaires even after a reminder or who stated on the provided coupons that they wished to withdraw, were omitted from further analyses ( Figure 1 ). No patients were excluded from analyses because of missing items. When a HADS questionnaire was partially incomplete, the anxiety and depression scale values were esti- mated by assuming that the missing item had a value equal to the average of those items which were present, provided that at least half of the items of the scale were present. 32, 33 No accepted standard exists as to what are the clinically significant numerical changes on anxiety and depression scales or for quality of life data. Differences of 10 points or more on the 0-100 point scales are regarded as clinically significant changes and perceptible to patients, whereas differences of 7 to 10 points represent questionable clinical importance in these publications. As such, differences of approximately 2 points representing a 10% change on the anxiety and depression scales, respectively, were taken to indicate clinical significance, while differences of 1.5 points (7%) were regarded as a probably meaningful change. This is in line with our previous publications and also suggested elsewhere. 27, 34, 35 All figures were produced in Excel, version 5.0, 36 while the SPSS statistical software version 6.1 37 was used for the statistical analyses. The study was approved by the Regional Ethical Committee and the institutional review boards at the two hospitals.
Results
Only 33 items (0.1%) were missing from the completed questionnaires, while 38 forms were not returned during follow-up, giving an overall compliance rate of 98%. Reliability was assessed by Cronbach's alpha 38 and ranged from 0.81 to 0.87 for the anxiety scale and from 0.77 to 0.88 for the depression scale at the different assessments. The anxiety and depression mean scores correlated (P Ͻ 0.0001) at all assessments for all groups with r ranging from 0.52 to 0.79.
Anxiety
The level of anxiety gradually decreased from baseline during follow-up for all groups, although a slight increase was seen at the 1-year assessment for the transplant groups ( Figure 2) . No statistically significant differences across groups were found. The level of anxiety in the ASCT group remained more stable at a slightly higher level compared with the SCT group. The highest and lowest levels were 5.8 (1 month pre-SCT) and 2.9 (8 months after) for the SCT group, 5.5 (baseline) and 4.4 (8 months after) in the ASCT group, and 6.0 (baseline) and 4.2 (after 1 year) in the CT group, respectively.
Depression
No statistically significant differences across groups were found for depression. The slope of the curve during follow- up was almost identical in the two transplant groups, although the ASCT group had slightly higher mean scores than the SCT group ( Figure 3 ). There was a marked increase from the assessment 1 month prior to transplant to the one 2 weeks post transplant (SCT: from 2.8 to 6.1, ASCT: from 3.9 to 6.4) in both groups. The curve then rapidly declined and stabilized at baseline levels after 4 months ( Figure 3 ). There were only minor fluctuations from baseline during follow-up in the CT group, with a range of mean scores from 2.3 to 3.4 ( Figure 3 ).
Cases
No statistically significant differences were found across groups regarding the number of anxiety cases (mean scale score у8) at any assessment (Figure 4) , although the percentage of cases was generally lower in the SCT group (range 9 to 25%) compared with the ASCT group (range 19 to 29%). This was most pronounced during follow-up, where the percentage of cases in the SCT group went down from 21% 2 weeks post SCT to 9% at 8 months, compared with a minor decline from 27% to 24% in the ASCT group. More fluctuations were found in the CT group, with 26% cases at baseline, 27% 4 months after start of chemotherapy and 15% after 1 year.
The percentage of depression cases in the SCT group peaked at 38% 2 weeks post SCT, and went down to 5% after 1 year, corresponding to 42% and 16%, respectively, in the ASCT group ( Figure 5 ). The percentage of cases in the CT group was eight after 1 year ( Figure 5 ). Of those defined as anxiety cases at the 1-year assessment, two of six SCT patients (33%), six of 12 ASCT patients (50%) and eight of 13 CT patients (62%) were also cases at baseline. The corresponding numbers for depression were none in the SCT group, three of eight (38%) in the ASCT group and three of seven (43%) in the CT group.
There were no significant differences in anxiety or depression scores for those who had relapsed at the 1-year assessment, compared with those who were free of disease. The 11 SCT patients who suffered from GVHD at the 1-year medical examination did not differ significantly from those with no signs of GVHD regarding the HADS scores. Low correlations between the Karnofsky performance status scores (KPS) and anxiety (r = Ϫ0.2) and depression (r = Ϫ0.2) were found after 1 year, while there was statistically significant correlation (r = Ϫ0.3, P = 0.002) between depression and KPS at the assessment 2 weeks post transplant.
Temporal trajectory
Data from those patients with completed questionnaires at the four selected time points (SCT: 41, ASCT: 47, CT: 82) showed that the mean anxiety and depression scores and percentages of cases were consistently lower in the SCT than in the ASCT group, although not statistically significant (Table 3) . The CT patients reported significantly less depression 1 month after start of chemotherapy compared with the SCT (P = 0.007) and ASCT group (P Ͻ 0.0001) 1 month after transplant. There were significantly more cases in the ASCT group (P = 0.003) than in the CT group at this assessment.
Multiple regression analyses were performed including the following background variables: age group (16-29, 30-39, 40-49 and 50-60), gender, patient group (dummy coded), living situation, relapse (after 1 year) and the baseline anxiety and depression scores, respectively, for the assessments other than baseline (Table 4) . These independent variables were entered into the model based on their possible influence on psychological distress and health-related quality of life. 27 Higher anxiety and depression scores at baseline were predictive of more anxiety and depression (P values Ͻ0.0001) at the subsequent assessments as indicated in Table 4 which also gives the regression coefficients (B) and the percent of variance (R square) accounted for by the sets of variables included. Treatment with ASCT was significantly related to more anxiety after 1 year, relative to the SCT group (P = 0.01), while belonging to the CT group was associated with less depression at the 1 month assessment (P Ͻ 0.0001), compared with the SCT group as in the univariate analyses. Advanced age indicated more depression at baseline (P = 0.003) and after 1 month (P = 0.005), while living alone (P = 0.005) was also significantly related to being more depressed. No significant differences were found between groups regarding age and living situation.
Logistic regression was used to examine whether imbalance in baseline prognostic factors (the same background variables as in the multiple regression) affected the group differences regarding number of cases (mean scale score у8) at the selected time points. However, this did not change any of the above conclusions (data not shown).
Fatigue
Patients who are treated with intensive combination chemotherapy are expected to be in a generally poor condition, both physically and psychologically. Fatigue is then a predominant symptom during and after treatment, and by definition, closely related to psychological distress.
One item in the depression scale is regarded as highly related to fatigue ('I feel as if I am slowed down'), and separate analyses were performed without this item. Significantly lower depression scores were found at all assessments for the scale scores based on six items (P values Ͻ0.0001) compared with the 'original' ones. Differences ranged from 0.5 to 1.3, with the greatest discrepancies at the times when the patients had the highest levels of depression; at baseline for the CT group and at 2 weeks and 1 month post transplant for the SCT and ASCT groups ( Figure 6 ).
An examination of item scores constituting the depression scale, revealed that the 'fatigue' item accounted for 21% and 22% of the total depression scores for the transplant groups and CT patients, respectively, at the times when depression peaked. At the 1-year assessment, when the patients reported a low level of depression, the percentage was similar (22%).
Discussion
The overall impression from this study is that the transplant patients reported relatively low levels of anxiety and depression, except during the time of isolation, contrary to our anticipation when compared with other reports of psychological distress in transplant patients and other cancer survivors. 20, 21, 23, 25, 18 The course of psychological distress in the CT group was more in line with our expectations, peaking shortly after diagnosis. The time of assessments during the course of disease is important in this respect, in line with studies indicating that psychological distress reaches the highest levels in the time between diagnoses and start of treatment. 26, 39, 40 The prospective design shows a slight decline in anxiety in the SCT group and relatively stable levels (ASCT group) during hospitalization and follow-up, and an increase in depression during hospitalization before it consistently declined in both groups. This pattern of change was in line with two prospective studies employing the State Trait Anxiety Inventory (STAI) and the Zung Depression Inventory, 41 and the POMS, 6 but contradicted slightly with other studies reporting minor changes in psychological distress during follow-up assessed by the POMS 5 and Beck's Depression Inventory (BDI). 4 The level of psychological distress in the transplant patients was generally lower in this report compared with other studies employing the HADS scale. 20, 21, 23, 25 In a cross-sectional study of 50 patients assessed at a mean of 42 months post transplant, 21 the level of anxiety was higher than found at the 1-year assessment in our study (SCT: 5.0 vs 3.6, ASCT: 6.0 vs 4.8), as was the anxiety case rate in ASCT patients (20% vs 10%, cut-off у11). We did not find any significant differences in HADS scores with respect to type of transplant, consistent with other reports, [21] [22] [23] although there was more psychological distress among the ASCT than SCT patients, as reported elsewhere. 21 There were no significant differences between the CT group and the transplant groups regarding anxiety and depression from baseline during follow-up, although the baseline anxiety level was higher in the CT group than in the other two. A probable explanation might be that these patients had recently been diagnosed with cancer and were facing the start of chemotherapy, supported by findings from the psychological literature. 26, 39, 40 Particularly more depression, however, assessed by the HADS scale, has been found in CT patients compared to transplant patients. 20 When comparing those patients who completed the questionnaires at the four selected time points, we failed to find significant differences between the SCT and ASCT groups. The significant differences in depression between the transplant patients and the CT patients at the 1-month assessment (Table 3 ) must be viewed in relation to differences in the course of the disease and treatment across groups at these assessments. In this context it should be remembered that the CT group is merely a reference group, not a comparison group. The multivariate approach in this subgroup of patients showed that higher baseline scores were the strongest predictive factors for more anxiety and depression at subsequent assessments, as well as for anxiety cases after 1 year, as reported by other. 23, 41 Treatment with ASCT was associated with more anxiety after 1 year. A less favourable outcome in the ASCT group than in the SCT groups, is in line with our previous report of health-related quality of life. 27 When looking at the steep increase in depression from the assessment 1 month pre-transplant to the one 2 weeks post transplant, followed by the consistent decline down to baseline levels after 4 months, one might question whether this reflects a true depression. This could rather indicate a combination of depressed mood, somatic symptoms and treatment side-effects, especially since the peak occurred when the patients were in protective isolation or shortly thereafter. The fact that the same pattern was not found in the CT group where the side-effects from treatment were less intensive, that the discrepancies in mean depression scores were so great when the 'fatigue' item was taken out from the analyses, and the significant correlation between depression and the Karnofsky scores when the patients scored lowest regarding performance status, lends support to this. The relationship between the depression scale of the HADS and physical symptoms has been mentioned by other, 15, 17 and warrants further investigation. Thus, the higher levels of psychiatric distress reported from other studies might be explained by the use of questionnaires such as the BDI, which includes more somatic symptoms than the HADS.
No journal articles presenting HADS scores from general population samples exist at present to our knowledge, although warranted by clinicans. The Hopkins Symptom Checklist, however, was employed in a large Norwegian population survey, estimating the prevalence of anxiety cases to approximately 3.3% and depression cases to about 3.0%. 42 Thus, we found a higher level of psychological distress in all patient groups after 1 year compared with the general Norwegian population, particularly regarding anxiety, regardless of whether the lower or higher cut-off was used for case definition. This is in line with reports from other cancer survivors 13, 18 and consistent with studies in SCT or ASCT patients employing questionnaires which provide population data. 3, 4, 7, 10 The lack of assessment of prior psychological health and the great differences between the SCT and ASCT patients regarding previous treatment experiences as discussed previously 27 might be regarded as a limitation of this study. This is especially related to the time elapsed between initial diagnosis which might date years back and the extent of previous treatment, which might have influenced the patients' psychological distress during the course of treatment with HDC. The fact that some of the assessments in the CT group coincided with chemotherapy treatment might also have affected the reported levels of anxiety and depression. A longer follow-up period going beyond 1 year would also be advantageous, because a case definition after 1 year does not necessarily indicate persisting psychopathology, but might reflect a prolonged process of recovery.
On the other hand, this study which is probably the largest prospective study employing the HADS in SCT and ASCT patients, with a good compliance rate, includes multiple assessments, and compares the data with a concurrent group of conventionally treated lymphoma patients, provides new information about the temporal trajectory of anxiety and depression before, during and after high-dose chemotherapy. The additional reporting of data from the same number of patients at selected time points in order to reduce interpretive problems by different number of patients adds to this. It could be argued that the course of anxiety and depression should be focused on the four selected time points only, because then the same patients provide data. However, restricting analyses to the (healthier) subgroup of patients who survive longest results in underestimation of the problems experienced by those patients who die earlier. That is, the results would be biased and nonrepresentative of patients as a whole. We therefore decided to present our results both in terms of all patients alive at different time points and also (Table 3) to show the pattern in those who survive longer. We believe it is important and informative for clinicians to know the proportion of those currently alive who experience problems, as shown in our figures.
It is important to distinguish between significant, but transient psychological distress as a reaction to intensive cancer therapy compared with psychological morbidity, as classified by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 43 The case prevalence rates in studies like this do not necessarily reflect the true level of psychiatric disorders. The clinical challenge is to separate symptoms of a major depressive disorder which might encompass fatigue, insomnia and appetite loss from symptoms which are directly attributable to the cancer and/or its treatment, in order to make an accurate diagnosis of depression. 44 A recent study showed that physicians tended to underestimate the level of depressive symptoms in patients who were moderately to severely depressed. 45 An important question in this context is related to what are clinically significant changes. Although changes in scores of 10% or more are regarded as such, and even differences from 7% and up might be perceptible to patients, more research on this matter is warranted. Measures of anxiety and depression used on a routine basis in the clinical setting might help to identify patients who are in need of further psychiatric evaluation and those who might benefit from adjuvant psychological therapy, for example, educational intervention or social support groups. Another relevant question is how clinicians could assist in alleviating the increased levels of anxiety, in particular at the time of the 1-year assessment, which is obviously a mental strain for patients. If the lower cut-off for cases (у8) is used for screening purposes, the proportion of cases is likely to become high with too many false-positive cases. This might, however, raise the awareness of symptoms of anxiety and depression, which might be detrimental and reduce the patients' quality of life in the long run.
In conclusion, while the levels of anxiety declined or remained fairly stable from baseline during follow-up in this study, there was a remarkable peak in depression followed by a consistent decline. Furthermore, we found lower levels of psychological distress compared with other studies in SCT and ASCT patients. Nevertheless, particularly more anxiety relative to what has been reported from the general population was found 1 year after transplant or start of chemotherapy. Thus, we recommend that a validated screening tool for assessment of anxiety and depression is incorporated in the clinical setting at an early stage, to raise the awareness of patients' psychological distress among clinicians. Because a 1-year follow-up might be too short for complete recovery after this intensive treatment, the patients in this study are now being reassessed after 3 to 5 years. In order to investigate further the relationship between physical symptoms and the HADS scale, a specific questionnaire for assessment of fatigue in cancer patients is included at this assessment.
